Ethiopia’s journey toward ensuring pharmaceutical sovereignty has reached a new milestone. The nation is implementing strategic initiatives that treat pharmaceutical manufacturing not merely as an economic benefit, but as a matter of national survival and sovereignty.

A key pillar of this effort is the recently inaugurated Armauer Hansen Research Institute (AHRI), which serves as the technical backbone of the sector through its advanced laboratories and bioequivalence center.

The lessons learned from the COVID-19 pandemic have fundamentally reshaped Ethiopia's industrial policy. By aggressively reducing an import dependency that once exceeded 90%, domestic pharmaceutical production now covers 44% of the national demand. There is a firm commitment to increase this capacity to 55% in the near future.

Furthermore, the "ShieldVax Enterprise" project is underway with the goal of establishing Ethiopia as a vaccine manufacturing hub. This project aims for "End-to-End" manufacturing, covering everything from raw materials to the finished product within the country.

The manufacturing sector’s 58% performance in import substitution over the past nine months offers great hope for the health sector. Supported by scientific research and technology, the goal of achieving full self-sufficiency within the next five years is well within reach. As Ethiopia’s growth is built upon the health and productivity of its citizens, this journey toward sovereignty will continue to be strengthened.